



ELMAR JOURA

Austria

Personal statement

The past eight years in the ESGO Prevention Committee and the experience with more than twenty years of working on HPV vaccination in clinical trials and implementation work could contribute to the future achievements of the society.

Important parts of my work were in the field of vulvar disease, still an underrepresented field in gynecologic oncology. Through the Prevention Committee, the collaborations with centers in Africa has become important over the past few years. To achieve a substantial benefit for these countries, the implementation of Prevention and cost effective diagnostic tools and therapeutic agents is key.

Research directions have to be both, high end therapies and feasibility in low and middle income countries. Working at a high level institution, the global perspective has always be in mind.

Elmar A. Joura, M.D., is associated Professor and gynecological oncologist at the Medical University of Vienna, Austria and head of the clinic for colposcopy and vulvar disease. He worked in Tanzania, and together with Ron Jones at National Womens Hospital in Auckland and wrote his thesis on vulvar disease. Since 2001 Dr. Joura is investigator for HPV vaccine trials. He was president of EUROGIN in 2016 and is past president of the European college for the study of vulvovaginal disease (ECSVD). Dr. Joura has published more than 160 articles in peer- review journals and given more than 1000 lectures worldwide.

PUBLICATIONS

1. Kainz C, **E. Joura**, R. Obwegeser, B. Plöckinger, W. Gruber.
Wirksamkeit und Verträglichkeit von Tramadol mit oder ohne Antiemetikum
sowie von Pethidin zur geburtshilflichen Analgesie
Z.Geburtsh.u.Perinat. 196 (1992) 78-82 *, IF: 0.365

2. Hanzal E, G. Gitsch, **E. Joura**, Ch. Dadak, G. Breitenecker. Die Wertigkeit der
intraoperativen Schnellschnittuntersuchung in der Diagnostik des
Mammakarzinoms
Geburtshilfe und Frauenheilkunde 52 (1992) 161-164*, IF: 0.275

3. **Joura EA**, G. Gitsch, Ch. Kainz, G. Breitenecker
Klinische Einzelbeobachtung: Primäres Melanom der Cervix uteri Stadium FIGO
III
Geburtshilfe und Frauenheilkunde 52 (1992) 367-368*, IF: 0.365

4. Gitsch G, Ch. Kainz, **E. Joura**, B. Fröhlich, Ch. Biegelmayr, G. Tatra
Squamous cell carcinoma antigen, Tumor associated trypsin inhibitor and
Tissue polypeptide specific antigen in follow-up of stage III cervical cancer
Anticancer Research 12 (1992) 1247-1250 *, IF: 1.041

5. Kainz Ch., G. Gitsch, **E. Joura**, E. Hanzal, Ch. Dadak, W. Gruber
Entbindung bei Status post Sectio 1976-1991
Gynäkol Geburtsh Rundsch 1992;32(Suppl1): 74-75 +

6. **Joura EA**, G. Gitsch, Ch. Kainz, B. Fröhlich, Ch. Biegelmayr, H. Kölbl.
Serum-Tumormarker SCC, TATI, TPS: Aussage in der Nachsorge von Frauen
mit Zervixkarzinom
Gynäkol Geburtsh Rundsch 1992;32(Suppl1): 115 +

7. Kainz Ch., G. Gitsch, **E. Joura**, G. Breitenecker
p53 Protein bei Patientinnen mit Zervixkarzinom Stadium FIGO III
Gynäkol Geburtsh Rundsch 1992;32(Suppl1): 116 +

8. **Joura EA**, G. Gitsch, Ch. Kainz, E. Berger, G. Breitenecker
Kasuistik eines primär bestrahlten Melanoms der Cervix uteri
Gynäkol Geburtsh Rundsch 1992;32(Suppl1): 134 +

9. Gitsch G, Ch. Kainz, **E. Joura**, G. Breitenecker
Mutant p53 protein in patients with stage III cervical cancer
Anticancer Research 12 (1992) 2241-2 *, IF: 1.041

10. Kainz Ch., G. Gitsch, **E. Joura**, B. Fröhlich, Ch. Biegelmaier. Squamous cell
carcinoma antigen and Tissue polypeptide specific antigen in follow up of
cervical cancer
J Tumor Marker Oncology 7(1992) 3: 40

11. Kainz Ch., G. Gitsch, **E. Joura**, G. Breitenecker
p53 Protein als Prognosefaktor bei Patientinnen mit Zervixkarzinom
Arch.Gynecol.Obstet. (1992) Suppl.1025-27 ,IF: 0.063
12. **Joura EA**, G. Gitsch, Ch. Kainz, H. Koelbl, G. Breitenecker
Mutant p53 protein in stage III cervical cancer
Anticancer Research 12 (1992) 1862 +, IF: 1.041
13. Sliutz G, B. Schäfer, **E. Joura**, A. Hammerle, Ch. Dadak
Geburtshilfliches Management bei Patientinnen mit HELLP-Syndrom
Z.Geburtsh. u. Perinat.197 (1993) 112-118 *, IF: 0.311
14. Kainz Ch., A. Reinthaller, **E. Joura**, Ch. Biegelmayr, F. Fischl
Cathepsin D in stimulierten Follikeln
Fertil. Reprod. 3 (1993) 12
15. Kainz Ch., **E. Joura**
Hyperreactio luteinalis in der Schwangerschaft
Geburtshilfe und Frauenheilkunde 54 (1994) 59-61 *, IF: 0.366
16. Kainz Ch., G. Häusler, **E. Joura**, G.Sliutz, G. Gitsch, A. Reinthaller
Radiosurgery in Diagnosis and Therapy of Cervical Dysplasia
Gynaecological Endoscopy 3/1 (1994) 54
17. Tempfer C, Ch. Kainz, **E.A. Joura**, A. Reinthaller, G. Breitenecker
Einfluß von Alter und HPV-Infektion auf die Verlässlichkeit der Zervixzytologie
Gynäkol Geburtshilfliche Rundsch 1994, 34 (Suppl) 82-3+
18. **Joura EA**, A. Lösch, Ch. Kainz, E. M. Joura, Ch. Dadak, G. Breitenecker
Die Extensive Intraduktale Komponente (EIC) als Prognosefaktor beim
Invasiven Duktalen Mammakarzinom (DIC)
Gynäkol Geburtshilfliche Rundsch 1994; 34 (Suppl) 143-4+
19. Sam Ch., **E.A. Joura**, Ch. Kainz, Ch. Dadak
Einfluß des hohen Alters auf das Überleben beim Mammakarzinom
Gynäkol Geburtshilfliche Rundsch 1994; 34 (Suppl) 145-6+
20. Reinthaller A, Ch. Kainz, C. Tempfer, **E. Joura**
Radiochirurgische Behandlung der zervikalen intraepithelialen Neoplasie
Gynäkol Geburtshilfliche Rundsch 1994,34:98-101 +
21. **Joura EA**, Ch. Kainz, E.M. Joura, R. Böhm, W. Gruber, G. Gitsch.
Vergleich der Oberflächenspannungsmessung mit der Bestimmung der L/S-
Ratio zur Vorhersage der fetalen Lungenreife
Z.Geburtsh.u.Perinat 199 (1995) 78-80 *, IF: 0.311
22. **Joura EA**, Ch. Sam, D. Bancher, E.M. Joura, J.C. Huber
The impact of 3 α -androstenediol-glucuronid on peripheral androgenisation
Gynecological Endocrinology 9 (1995) Suppl. +, IF: 0.815

23. Sam Ch., **E.A. Joura**, D. Bancher, H. Zeisler, E.M. Joura, Ch. Dadak, J.C. Huber
Androgens in Pregnancy and Puerperium
Gynecological Endocrinology 9 (1995) Suppl. +, IF: 0.815
24. **Joura EA**, A. Lösch, Ch. Kainz, Ch. Sam, E.M. Joura, Ch. Dadak, G. Gitsch, G. Breitenecker. Breast Cancer: Extensive intraductal component in infiltrating ductal carcinoma has no impact on lymphonodal involvement and survival
Anticancer Research 1995;15: 2285-6. *, IF: 1.066
25. Bancher-Todesca D, H. Zeisler, A. Obermair, **E.A. Joura**, A. Bodisch, M. Thoma, Ch. Kainz, G. Breitenecker, A. Reinthaller, G. Gitsch.
Sarcomabotryoides (embryonal rhabdomyosarcoma) of the uterine cervix. Case Report and current management.
Anticancer Research 15 (1995) 5A, 1719-1720 +, IF: 1.066
26. **Joura EA**, D. Bancher-Todesca, A. Lösch, H. Zeisler, A. Obermair, G. Breitenecker, G. Gitsch.
Vulvar Intraepithelial Neoplasia (VIN): Diagnosis value of non-invasive methods.
Anticancer Research 15 (1995) 5A, 1817 +, IF: 1.066
27. Obermair A, D. Bancher-Todesca, A. Bodisch, M. Thoma, **E.A. Joura**, C. Kurz, T. Wagner, A. Kaider, P. Sevelde, G. Gitsch. Angiogenesis parameters, as microvessel density and vessel invasion, rather than established prognostic factors influence breast cancer prognosis.
Anticancer Research 15 (1995) 5A, 1826. +, IF: 1.066
28. **Joura EA**, A. Obermair, A. Lösch, Ch. Sam, D. Bancher-Todesca, E.M. Joura, G. Breitenecker, G. Gitsch.
Histopathological prognostic factors in infiltrating ductal carcinoma of the breast
Anticancer Research 15 (1995) 5A, 1829-1830 +, IF: 1.066
29. **Joura EA**, A. Lösch, H. Zeisler, G. Gitsch, G. Breitenecker, A. Reinthaller
Klinische Diagnostik der vulvären Dysplasien
Wiener Klinische Wochenschrift 1995 (107) 788 +, IF: 0.268
30. Zeisler H, Ch. Sam, D. Bancher, Ch. Dadak, **E.A. Joura**
Der Einfluß des Intervalls vom Blasensprung zur Geburt auf das Fetal-outcome
Wiener Klinische Wochenschrift 1995 (107) 788 +, IF: 0.268
31. Sator MO, Gruber D, **Joura EA**
Hormonal influences on intraocular pressure [letter]
Lancet 1996 (348) 761-2 ***, IF: 17.948
32. **Joura EA**, H. Zeisler, G. Gitsch. Die therapeutische und systemische Wirkung von topischem Testosteron bei Lichen sclerosus
Arch Gynecol Obstet 258(1996) (Suppl 1) 108 +, IF: 0.166
33. Zeisler H, D. Bancher-Todesca, **E.A. Joura**, A. Reinthaller.
Fallbericht und therapeutisches Management des embryonalen

- Rhabdomyosarkoms der Cervix uteri im Stadium I.
Arch Gynecol Obstet 258 (1996) (Suppl 1) 180 +, IF: 0.166
34. **Joura EA**, Geusau A, Schneider B, Söregi G, Huber JC. Serum 3 α -androstenediol-glucuronid is decreased in non-hirsute women with acne vulgaris
Fertil Steril 1996; 66:1033-5 ***, IF: 2.936
35. **Joura EA**, H. Zeisler, D. Bancher-Todesca, M. O. Sator, B. Schneider, G. Gitsch
Short-term effects of topical testosterone in vulvar lichen sclerosis
Obstet Gynecol 1997;89:297-9 ***, IF: 2.427
36. Zeisler H, **E.A. Joura**, P. Moeschl, U. Maier, H. Koelbl
Dilemmas of preoperative staging in recurrent cervical cancer.
Acta obstet gyn scan 1997;76:474-477. *, IF:0.872
37. Frigo P, Lang C, **Joura E**, Grabenwöger F, Kölbl H.
Successful treatment of a high risk choriocarcinoma at FIGO stage IV (WHO score 12) A case of high risk choriocarcinoma
European Journal of Gynaecological Oncology 18 (1997), 451-4.
38. Zeisler H, **E.A. Joura**, D. Bancher-Todesca, E. Hanzal, G. Gitsch
Pregnancy outcome in patients with a history of cone-biopsy
J Reprod Med 1997;42:390-2. *, IF: 0.719
39. Sator MO, Franz P, Kirschhofer K, Tschugguel W, Gruber D, Zeisler H, **Joura E**, Huber JC
Tibolone alters auditory brain stem responses in postmenopausal women
Acta obstet gyn scan 1997;76 (Suppl.167:5):60. +, IF: 0.872
40. Frigo P, Lang C, **Joura E**, Grabenwöger F, Kölbl H.
Successful treatment of a high risk choriocarcinoma at FIGO stage IV (WHO score 12) A case of high risk choriocarcinoma
Gynecol Obstet Invest 1997;44:211-3. *, IF: 0.641
41. **Joura EA**
Vulväre intraepitheliale Neoplasien (VIN) - eine Erkrankung mit steigender Inzidenz
Speculum 1997;15/3: 23-6. ,**Einladung**
42. Zeisler H, Mayerhofer K, **Joura EA**, Sator MO, Kainz C
Psychological burden of women with mild CIN
Oncology Reports 1997;4:1063-5. +, IF: 0.476
43. Sator MO, **E.A. Joura**, P. Frigo, D.M. Gruber, A. Hommer, J.C. Huber
Hormone replacement therapy and intraocular pressure
Maturitas 1997;28:55-58 **, IF: 1.975
44. Zeisler H, Sator M, Sam C, **Joura EA**
Fetale Azidose bei frühzeitigem Blasensprung

Arzt + Praxis 1997;51:735-7.

45. **Joura EA**. Epidemiologie, Vorstufen und Diagnostik des Vulvakarzinoms. In: Onkologisch (Hrsg.: Österreichische Krebshilfe) 11/1997:19-21 , **Einladung**
46. Zeisler H, **EA Joura**, M Sator, R Lehner, C Schatten, P Husslein.
Prophylaktische Cerclage bei konisierten Frauen ?
Perinatal Medizin 1997;9:136
47. **Joura EA**, Sator MO, Geusau A, Zeisler H, Söregi G, Huber JC
Die klinische Wertigkeit von 3α -Androstanediol-Glucuronid bei hirsuten Frauen
Wiener Klinische Wochenschrift 1997;109:919-21. *, IF:0.411
48. Sator MO, **E.A. Joura**, T. Golaszewski, D. Gruber, P. Frigo, M. Metka, A. Hommer, J.C. Huber. Treatment of menopausal keratoconjunctivitis sicca with topical oestradiol
Brit J Obst Gynaecol 1998;105:100-2. ***, IF: 2.299
49. **Joura EA**, Zeisler H, Sator MO
Epidemiologie und klinische Wertigkeit von echten Nabelschnurknoten
Wien Klin Wochenschrift 1998;110:232-5 *, IF: 0.583
50. Gruber D, Sator MO, **Joura EA**, Kokoschka EM, Huber JC
Topical CPA-treatment in women with acne: A placebo-controlled trial
Arch Dermatol 1998;134:459-63 ***, IF 2.546
51. Zeisler H, Tempfer C, **Joura EA**, Sliutz G, Koelbl H, Wagner O, Kainz C.
Serum interleukin-1 in ovarian cancer patients
Eur J Cancer 1998; 34:931-3 **, IF: 2.743
52. Sator MO, Akramian J, **Joura EA**. Nessmann A, Wedrich A, Gruber D, Metka M, Huber JC. Reduction of intraocular pressure in a glaucoma patient undergoing HRT
Maturitas 1998;29:93-5 *, IF: 1.489
53. Zeisler H, Mayerhofer K, **Joura EA**, Bancher-Todesca D, Reinthaller A.
Embryonal Rhabdomyosarkoma of the uterine cervix: Case report and review of literature
Gynecol Oncol 1998; 68:78-83 **, IF: 1.636
54. Lösch A, Tempfer C, Kohlberger P, **Joura EA**, Denk M, Zajic B, Breitenacker G, Kainz C. Prognostic value of Cathepsin D expression and association with histomorphological subtypes in breast cancer
Br J Cancer 1998; 78:205-9 ***, IF: 4.449
55. Sam CE, Schmid-Stino N, Joura EM, **Joura EA**. Die Akzeptanz der Videokolposkopie. Speculum 1998;16(Suppl):8
56. **Joura EA**. Problemzone Vulva
Speculum 1998;16 (Suppl):19

57. Zeisler H, Tempfer C, Schatten C, Sator M, **Joura EA**, Husslein P.
Adhäsionsmoleküle und Präeklampsie.
Speculum 1998; 16 (Suppl):28
58. **Joura EA**. Sectio caesarea: "Evidence based".
Speculum 1998;16 (Suppl):74
59. Gruber D, Sator M, Kirchengast S, **Joura EA**, Huber JC. Effect of percutaneous androgen replacement therapy on body composition and body weight in postmenopausal women.
Maturitas 1998; 29:253-9 * , IF: 1.489
60. **Joura EA**, Jones RW. Is vulvar cancer potentially preventable?
J Reprod Med 1998; 43:617-8 + , IF: 0.783
61. **Joura EA**, Zeisler H, Lösch A, Sator MO, Müllauer-Ertl S
Differentiation of VIN and NNED: The toluidineblue-test
J Reprod Med 1998;43:671-4 * , IF: 0.783
62. **Joura EA**, Husslein PW. Maßnahmen nach operativer Entbindung.
Gynäkologe 1998;31:794-8 **Einladung** + , IF: 0.346
63. Yücel Y, **Joura EA**, Zeisler H, Seifert M, Chalubinski K, Husslein P.
Minimaler Wundverschluß bei Sectio caesarea.
Arch Gynecol Obstet 1998;266 (Suppl): 4 , IF: 0.182
64. Zeisler H, Tempfer C, Schatten C, Sator M, **Joura EA**, Husslein P
Klinische Bedeutung von Adhäsionsmolekülen bei der Präeklampsie
Arch Gynecol Obstet 1998;266 (Suppl):42 , IF: 0.182
65. Kohlberger PD, **Joura EA**, Bancher D, Gitsch G, Breiteneker G, Kieback DG.
Androgenrezeptorexpression in Lichen sclerosus der Vulva
Arch Gynecol Obstet 1998;266 (Suppl):132 , IF: 0.182
66. **Joura EA**, Jones RW.
Eine Analyse der Anamnese von 102 Frauen mit invasivem Vulvakarzinom.
Arch Gynecol Obstet 1998;266 (Suppl):132 , IF: 0.182
67. Sator MO, **Joura EA**, Gruber DM, Wieser F, Jirecek S, Tschugguel W, Huber JC.
The effect of hormone replacement therapy on carotid arteries: measurement with a high frequency ultrasound system.
Maturitas 1998;30:63-8 * , IF: 1.489
68. Kohlberger PD, **Joura EA**, Bancher-Todesca D, Gitsch G, Breiteneker G, Kieback DG. Evidence of androgen receptor expression in lichen sclerosus: an immunohistochemical study. J Soc Gynecol Invest 1998; 5:331-3** , IF: 2.000
69. **Joura EA**, Yücel Y, Zeisler H, Seifert M, Chalubinski K, Husslein P.
Vereinfachter Wundverschluß bei Sectio caesarea.

Geburtsh Frauenheilk 1998;58:651-3

*, IF:0.395

70. **Joura EA**, Zeisler H, Lösch A, Sator MO, Müllauer-Ertl S
Differentiation of vulvar intraepithelial neoplasia and nonneoplastic epithelial disorders: The toluidineblue-test
Obstet Gynecol Surv 1999; 54: 28-9
71. **Joura EA**. Lichen sclerosus- neue Aspekte: Ein Überblick für die Praxis.
Gyn-aktiv 1999/1:35-9 , Einladung
72. **Joura EA**. Diagnose und Therapie der vulvären intraepithelialen Neoplasie (VIN)
Foto-Medico 1999;10(42):5-8 , Einladung
73. **Joura EA**, Husslein P.
Die Technik der Sectio caesarea – eine aktuelle Literaturübersicht für die Praxis.
Speculum 1999;17/1:8-11. , Einladung
74. Sator MO, **Joura EA**, Gruber D, Obruca A, Zeisler H, Ehgartner C, Huber JC
Non-invasive detection of alterations of the carotid artery in pregnant women with high frequency ultrasound
Ultrasound Obstet Gynecol 1999;3:260-2 **, IF:2.196
75. **Joura EA**, Husslein P. Sectio caesarea - das Wiener Modell
Gyn-aktiv 1999/1:34-5. , Einladung
76. Sator MO, Wieser F, Gruber DM, **Joura EA** , Huber JC
Trends in the prescription of psychotropic drugs and hormone substitutes in Austria
Wien Klin Wochenschr 1999;111:402-5. *,IF: 0.583
77. **Joura EA**, Lösch A, Müllauer-Ertl S, Leodolter S. Vulväre Neoplasien bei jungen Frauen.
Gynäkol Geburtshilfliche Rundschau 1999;39:77 ,IF:0.103
78. Lösch A, Zeisler H, Sator MO, Müllauer-Ertl S, **Joura EA**. Der Toluidinblau-Test bei vulvärer intraepithelialer Neoplasie.
Gynäkol Geburtshilfliche Rundschau 1999;39:83 ,IF:0.103
79. Schulz-Lobmeyr I, Zeisler H, Pateisky N, Husslein P, **Joura EA**.
Die Kristeller-Technik: Eine prospektive Untersuchung.
Gynäkol Geburtshilfliche Rundschau 1999;39:95 ,IF:0.103
80. Zeisler H, Jirecek S, Schatten C, Sator M, **Joura EA**, Husslein P.
Die klinische Bedeutung erhöhter Adhäsionsmoleküle bei präeklampsischen Frauen.
Gynäkol Geburtshilfliche Rundschau 1999;39:102 ,IF:0.103
81. Jones RW, **Joura EA**. An analysis of the history and clinical findings of 102 women with carcinoma of the vulva: evidence of diagnostic delay

94. Rabl M, Gregor H, Sam CE, **Joura EA**.
Sectio caesarea: Offenes Peritoneum und subfasziales Hämatom.
Geburtsh Frauenheilk 2000;60: 276-7 * , IF: 0.204
95. Hohlagschwandtner M., Schatten C., Tempfer C., Jirecek S., **Joura E. A.**,
Husslein P., Zeisler H. Serum Adhäsionsmoleküle bei Präeklampsischen Frauen
Speculum 2000;18(Suppl):22
96. Nather A., Zeisler H., Schulz-Lobmeyr I., Husslein P., **Joura E. A.**
Offenes Peritoneum bei der Sectio caesarea – eine Nachuntersuchung
Speculum 2000;18(Suppl):22-3
97. Hohlagschwandtner M., Chalubinski K., Husslein P., **Joura EA**.
Ist die obligate Blasenpräparation bei Sectio caesarea notwendig?
Speculum 2000;18(Suppl):23
98. Mayerhofer K., Bodner K., Bodner-Adler B., **Joura EA**, Aktas C., Rabl M.,
Kalmar B., Kaider A., Schulz-Lobmeyr I., Wagenbichler P., Husslein P.
Klassischer Dammschutz – Ende eines Mythos? Ergebnisse einer prospektiv-
randomisierten multizentrischen Studie mit 1076 Frauen
Speculum 2000;18(Suppl):49
99. Schindl M., Birner P., Lösch A, Sam Ch., Klimont J., **Joura E. A.**
Häufigkeiten zervikaler Neoplasien bei jungen Frauen zwischen 1983-1997
Speculum 2000;18(Suppl):56-7
100. Lösch A., **Joura EA**, Breitenecker G., Lahodny J.
Das Leiomyosarkom der Vulva
Speculum 2000;18(Suppl):11-2
101. Zeisler H, Livingston JC, Hohlagschwandtner M, Schatten C, Tempfer C, **Joura EA**, Husslein P. Elevated serum levels of androgens and preclampsia
Hypertens Preg 2000;19(Suppl.1):18 +, IF: 0.750
102. **Joura EA**, Lösch A, Haider-Angeler MG, Breitenecker G, Leodolter S.
Trends in vulvar neoplasia: Increasing incidence of vulvar intraepithelial
neoplasia and invasive carcinoma of the vulva in young women.
J Reprod Med 2000;45: 613-5 * , IF:0.820
103. Kucera E, Helbich T, Klem I, Schurz B, Sliutz G, Leodolter S, **Joura EA**.
Systemic methotrexate treatment of interstitial pregnancy - Magnetic resonance
imaging (MRI) as a valuable tool for monitoring treatment
Wien Klin Wochenschr 2000;112:772-5 * , IF: 0.583
104. Schindl M, Lösch A, **Joura EA**.
Increasing incidence of vulvar neoplasia in young women.
J Reprod Med 2000;45:765 * , IF:0.820
105. Sam CE, Dobler-Girdziunaite D, Heinze G, **Joura EA**, Haller U, Walt H.
Bioadhesive gel for laser light protection

- Lasers Med Sci 2000;15:266-8 * , IF: 0.959
- 106.Sam CE, Rabl M, **Joura EA**.
Aneurysma der Arteria lienalis: Ruptur in der Schwangerschaft.
Wien. Klin Wochenschr 2000;112: 896-8 * , IF: 0.583
- 107.Schindl M, Birner M, Löscher A, Breitenrecker G, **Joura EA**. Solitary preperitoneal lipomyoma in a hysterectomized patient. Case Report with immunohistochemistry
Maturitas 2000;37:33-6 * , IF: 1.489
- 108.Zeisler H, Rabl M, **Joura EA**, Husslein P. Prenatal Acupuncture and serum prostaglandin E2 levels during the first stage of labor
Geburtsh Frauenheilkd 2000;60:638-40 * , IF: 0.204
- 109.Zeisler H, Husslein P, Tempfer C, Jirecek S, Hohlagschwandtner M, **Joura EA**.
Serum levels of estrogens in women with preeclampsia
Am J Obstet Gynecol 2001;184:S79 + , IF: 2.519
- 110.Mayerhofer K, Bodner K, Bodner-Adler B, Schindl M, Kaider A, Hefler L, Zeillinger R, Leodolter S, **Joura EA**, Kainz C. Interleukin-8 serum level shift in patients with ovarian carcinoma undergoing paclitaxel-containing chemotherapy. Cancer. 2001;91:388-93. ** , IF: 3.611
- 111.**Joura EA**, Nather A, Husslein P. Non-closure of peritoneum and adhesions: The repeat cesarean section. [letter]
Acta Scand Obstet Gynecol 2001;80:286 * , IF: 1.209
- 112.**Joura EA**. Die gynäkologische Untersuchung.
In: Lehrbuch der Frauenheilkunde (Band 1), Husslein P et al. (Ed.).
Verlag Wilhelm Maudrich Wien-München-Bern 2001
- 113.**Joura EA**. Erkrankungen der Vulva.
In: Lehrbuch der Frauenheilkunde (Band 1), Husslein P et al. (Ed.).
Verlag Wilhelm Maudrich Wien-München-Bern 2001
- 114.**Joura EA**. Erkrankungen der Vagina.
In: Lehrbuch der Frauenheilkunde (Band 1), Husslein P et al. (Ed.).
Verlag Wilhelm Maudrich Wien-München-Bern 2001
- 115.**Joura EA**. Lichen sclerosus and vulvar cancer.
Eur J Gynecol Oncol 2001;22(S):9 ,IF: 0.562
116. Zeisler H, Mayerhofer K, **Joura EA**, Tempfer C.
Serum interleukin 1 in ovarian cancer patients.
Eur J Gynecol Oncol 2001;22(S):86 ,IF: 0.562
- 117.**Joura EA**, Reinthaller A. Vulvakarzinom.
In: Manual der gynäkologischen Onkologie. Arbeitsgemeinschaft für gynäkologische Onkologie der ÖGGG (Hrsg.)

MedMedia Verlag Wien, 2001; 15-26.

- 118.Nather A, Hefler L, Sami A, Leodolter S, **Joura EA**.
SCC Antigen als Prädiktor inguinofemoraler Lymphknotenmetastasierung bei patientinnen mit Vulvakarzinom.
Speculum 2001;19(Suppl. 1): 16-7
- 119.Schulz-Lobmeyr I, Schindl M, **Joura EA**.
CA 125 und Lymphknotenmetastasierung beim Endometriumkarzinom
Speculum 2001;19(Suppl. 1): 24-5
- 120.Hohlagschwandtner M, Chalubinski K, Husslein P, **Joura EA**.
Ultraschallbefunde nach Sectio caesarea: Blasenpräparation versus Verzicht auf Blasenpräparation
Speculum 2001;19(Suppl. 1): 28-9
- 121.Nather A, Zeisler H, Sam CE, Husslein P, **Joura EA**. Offenes Peritoneum bei Sectio caesarea: Ergebnisse der Re-Sectio.
Speculum 2001;19(Suppl. 1): 29
- 122.Schindl M, Janschek E, **Joura EA**. Offenes Peritoneum in der vaginalen Hysterektomie
Speculum 2001;19(Suppl. 1): 50-1
- 123.Hohlagschwandtner M, Chalubinski K, Nather A, Husslein P, **Joura EA**.
Versorgung der Uterotomie mit Fortlaufnaht oder Einzelknopfnähten:
Ultraschallbefunde nach Sectio caesarea
Speculum 2001;19(Suppl. 1): 51
- 124.Nather A, Zeisler H, Sam CE, Husslein P, **Joura EA**.
Offenes Peritoneum bei Sectio caesarea: Die Resectio
Wien Klin Wochenschr 2001;113:451-3 *, IF: 0.646
- 125.Lösch A, **Joura EA**, Breiteneker G, Lahodny. Leiomyosarcoma of the vulva.
J Reprod Med 2001;45:609-12 *, IF:0.820
- 126.Birner P, Bachtiry B, Dreier B, Schindl M, **Joura EA**, Breiteneker G,
Oberhuber G. Signal-amplified colorimetric in-situ hybridization for assessment of human papillomavirus infection incervical lesions
Modern Pathol 2001;14:702-9 ***, IF: 3.241
- 127.Nather A, Zeisler H, Sam CE, Husslein P, **Joura EA**.
Offenes Peritoneum bei Sectio caesarea: Ergebnisse der Re-Sectio.
Gynäkol Geburtshilfliche Rundsch 2001;41:132 +, IF: 0.228
- 128.Gregor H, Sam CE, Reinthaller A, **Joura EA**.
Port-site metastasis after laparoscopic lymphnode staging for cervical cancer.
J Am Assoc Gynecol Laparosc 2001;8:591-593. *, IF: 1.368
- 129.Bodner-Adler B, Bodner K, **Joura EA**, Husslein P, Wagenbichler P, Kaider A, Mayerhofer K. Einfluss der unterschiedlichen Geburtspositionen auf mütterliche

- Geburtsverletzungen und kindliche Parameter während spontaner vaginaler Geburt Geburtsh u Frauenheilk 2001;61:766-70. *, IF: 0.669
130. Hohlagschwandtner M, Ruecklinger E, Husslein P, **Joura EA**.
Is the formation of a bladderflap at cesarean necessary? A randomized trial
Obstet Gynecol 2001;98:1089-92 **, IF: 2.201
131. Girardi F, Pickel H, **Joura EA**, Breiteneker G, Gitsch G, Graf AH, Neunteufel W. Leitlinien für Diagnose und Therapie intraepithelialer Neoplasien und frühinvasiver Karzinome des unteren Genitaltraktes der Frau (Cervix uteri, Vagina, Vulva), erstellt von der AGK (Arbeitsgemeinschaft für Kolposkopie in der ÖGGG)
Gynäkol Geburtshilfliche Rundsch 2001;43:197-200+, IF: 0.228
132. **Joura EA**, Nather A, Hohlagschwandtner M, Husslein P.
Peritoneal closure and adhesions [letter]
Hum Reprod 2002;17:249 ***, IF: 2.987
133. **Joura EA**. Epidemiology, diagnosis and treatment of VIN.
Curr opin obstet gynecol 2002;14:39-43 Invitation *, IF: 1.108
134. Rabl M, **Joura EA**, Yücel Y, Egarter C.
A randomised trial of vaginal prostaglandin E₂ for induction of labour: Insert versus tablet
J Reprod Med 2002;47:115-9 *, IF: 0.777
135. Hohlagschwandtner M, Chalubinski K, Nather A, Husslein P, **Joura EA**.
Sectio caesarea ohne Blasenpräparation: Eine sonographische Nachuntersuchung.
Geburtsh u Frauenheilk 2002;62:163-6. *, IF: 0.699
136. Tempfer C, **Joura EA**, Leodolter S. FUTURE- HPV Studie am AKH Wien
Gyn-aktiv 1/2002
137. **Joura EA**, Hohlagschwandtner M. [Reply]
Is the formation of a bladderflap at cesarean necessary? A randomized trial
Obstet Gynecol 2002;99:677-8 **, IF: 2.196
138. Janschek E, Hohlagschwandtner M, Nather A, Schindl M, **Joura EA**.
Offenes Peritoneum bei vaginalen Hysterektomien
Gynäkol Geburtshilfliche Rundsch 2002;44:41 +, IF: 0.228
139. Nather A, Hohlagschwandtner M, Sami A, Husslein P, **Joura EA**.
Offenes Peritoneum bei der Sectio caesarea- Beeinflussung der Fertilität?
Gynäkol Geburtshilfliche Rundsch 2002;44:48-9 +, IF: 0.228
140. Mayerhofer K, Bodner-Adler B, Bodner K, Rabl M, Kaider A, Wagenbichler P, **Joura EA**, Husslein P. Traditional care of the perineum during birth: A prospective, randomized, multicenter study of 1,076 women
J Reprod Med 2002;47:477-82 *, IF: 0.777

141. Hefler L, Tempfer C, **Joura EA**, Leodolter S. HPV- Weltweit größte Impfstudie: Gyn-aktiv 2002/3:22-3.
142. **Joura EA**. Atrophe Veränderungen an der Vulva. Gyn-aktiv 2002/3:36-7.
143. Nather A, Hohlagschwandtner M, Sami A, Husslein P, **Joura EA**. Peritoneal closure and future fertility. Fertil Steril 2002;78:424-5 *** , IF:2.960
144. Nather A, Sami A, Hefler L, Leodolter S, **Joura EA**. Serum levels of squamous cell carcinoma antigen as a predictor of inguinofemoral lymph node metastasis in patients with vulvar cancer J Reprod Med 2002;47:718-20 *, IF:0.777
145. **Joura EA**. Therapie präinvasiver Neoplasien. Gyn-aktiv 2002/4:40-3.
146. Hohlagschwandtner M, Chalubinski K, Nather A, Husslein P, **Joura EA**. Continuous versus interrupted sutures for single-layer closure of uterine incision at cesarean section. Arch gynecol obstet 2002;99:online *, IF: 1.00
147. Janschek E, Hohlagschwandtner M, Nather A, Schindl M, **Joura EA**. Non-closure of the peritoneum at vaginal hysterectomy Arch gynecol obstet 2002;99:online *, IF: 1.00
148. **Joura EA**. Epidemiology and precursors of vulvar cancer. JWI 2002;4:126-9 CME article,
149. Hohlagschwandtner M, Knofler M, Ploner M, Zeisler H, **Joura EA**, Husslein P. Basic fibroblast growth factor and hypertensive disorders in pregnancy. Hypertens Pregnancy 2002;21:235-41. *, IF: 1.217
150. Hohlagschwandtner M, Chalubinski K, Nather A, Husslein P, Joura EA. Continuous vs interrupted sutures for single-layer closure of uterine incision at cesarean section. Arch Gynecol Obstet. 2003 Apr;268(1):26-8.
151. Janschek C, Hohlagschwandtner M, Nather A, Schindl M, Joura A. A study of non-closure of the peritoneum at vaginal hysterectomy. Arch Gynecol Obstet. 2003 Feb;267(4):213-6.
152. Jirecek S, Joura EA, Tempfer C, Knöfler M, Husslein P, Zeisler H. Elevated serum concentrations of androgens in women with pregnancy-induced hypertension Wien Klin Wochenschr 2003;115:162-7. *, IF 0.646
153. Nather A, Mayerhofer K, Grimm C, Hefler L, Leodolter S, Obermair A, **Joura EA**. Thrombocytosis and anaemia in women with recurrent ovarian cancer prior to a second line chemotherapy.

Anticancer Res 2003;23:2991-4

*, IF: 1.447

154. Schindl M, Birner P, Reingrabner M, **Joura EA**, Husslein P, Langer M. Elective cesarean section vs. Spontaneous delivery: A comparative study of birth experience.

Acta scand gynaecol obstet 2003; 82:834-40

*, IF: 1.209

155. **Joura EA**, Nather A, Hohlagschwandtner M, Husslein P. The impact of a single- or double-layer closure on uterine rupture. [letter]
Am J Obstet Gynecol 2003;189:895

156. Joura EA Humane Papillomaviren in der Gynäkologie.

Der Mediziner/Facharzt Gynäkologie/Urologie 2004;13/1:4-6

157. **Joura EA**. Humane Papillomviren und Zervixkarzinom: Gegenwart und Zukunft der Impfung

Gynakol Geburtshilfliche Rundsch. 2004;44:142-5

158. Hohlagschwandtner M, **Joura EA**, Husslein P. Empfehlung der Österreichischen Gesellschaft für Gynäkologie und geburtshilfe zur Technik der sectio caesarea.

Speculum 2004;2:18-9.

159. Hohlagschwandtner M, **Joura EA**. Sectio caesarea: Das bauchfell ruhig offenlassen. Ärztliche Praxis Gynäkologie 2004;2:10

160. Dörfler D, Mittermayer C, Mayerhofer K, Sam C, **Joura EA**.

HPV Infektionen bei Kindern

Arch Gynecol obstet 2004;270:S23

161. **Joura EA**. Sectio caesarea und intrauteriner Fruchttod in der folgeschwangerschaft- ein Kommentar.

Speculum 2004;22:16-7

162. Grimm C, Six L, Tomovski C, Speiser P, **Joura E**, Zeillinger R, Sliutz G, Reinthaller A, Hefler LA. A common interleukin-6 promoter polymorphism in patients with vulvar cancer.

J Soc Gynecol Investig 2005 Dec;12:617-20.

**IF:2,887

163. Hefler LA, Sliutz G, Leodolter S, Speiser P, **Joura E**, Reinthaller A, Kohlberger P. Squamous cell carcinoma antigen serum levels as prognostic parameter in patients with early stage vulvar cancer.

Gynecol Oncol. 2005 Jun;97:904-7

**, IF: 2,083

164. **Joura EA**. Die Klinik der Humanen Papillomaviren. Die Zukunft liegt in der Impfung. Hausarzt 2005/5:19-21

165. **Joura EA**. Impfung gegen Humanen Papillomaviren

Neuer Apotheker 2005

166. **Joura EA**. HPV in der Schwangerschaft.
Gynaktiv 2005/6:22-3
167. **Joura EA**, Drähne A. Erkrankungen von Vulva und Zervix. In Bitschnau M. Drähne A. (Hrsg.) Homöopathie in der Frauenheilkunde. Elsevier Urban & Fischer, München 2006. 511-30
168. **Joura EA**. Die HPV- Impfung: Der aktuelle Stand der Entwicklung
Österr. Vereinigung für klinische Onkologie, Österr. Krebshilfe. (Herausgeber)
krebs:hilfe! 1/2006:42-3.
169. Six L, **Joura E**, Leodolter S. Die HPV-Impfstudie FUTURE
Gynaktiv 1/2006:31
170. **Joura E**. State of the Art – Vulväre Intraepitheliale Neoplasien.
Gynaktiv 5/2006:15-17
171. **Joura EA**, Leodolter S, Hernandez-Avila M, Wheeler CM, Perez G, Koutsky L, Garland SM, Harper DM, Tang GWK, Ferris DG, Steben M, Jones RW, Bryan J, Taddeo FJ, Bautista OM, Esser MT, Sings HL, Nelson M, Boslego J, Sattler C, Barr E, Paavonen J.
High sustained efficacy of a quadrivalent HPV (types 6/11/16/18) L1 virus-like particle (VLP) vaccine against vaginal and vulvar pre-cancerous lesions: a combined analysis (Educational lecture 54)
18th International Conference on Anticancer treatment (ICACT)
7.2. 2007, Paris
172. Schausberger C, Six L, Horvat R, **Joura EA**.
Groin Metastasis After Extensive Microinvasive Vulvar Cancer: A Case Report
J Reprod Med 2007;52:78-80 IF:0,867
173. **Six L, Joura EA**.
Zervixkarzinom: Österreichischer Impfausschuß empfiehlt HPV Impfung.
Wien Med Wochenschr 2007;157:130-2.
174. Six L, Polterauer S, Grimm C, Seebacher V, Tempfer C, Heinze G, **Joura E**, Reinthaller A, Hefler L. C-reactive protein serum levels are closely associated with lymph node status, but not with prognosis in patients with vulvar cancer.
Eur J Obstet Gynecol Reprod Biol 2008;137:217-21 *,IF:1,565
175. **Joura EA**, Leodolter S, Hernandez-Avila M, Wheeler CM, Perez G, Koutsky LA, Garland SM, Harper DM, Tang GW, Ferris DG, Steben M, Jones RW, Bryan J, Taddeo, FJ, Bautista OM, Esser MT, Sings HL, Nelson M, Boslego JW, Sattler C, Barr E, Paavonen J. Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials.
Lancet. 2007 May 19;369:1693-702
***,IF:28,638

176. Kohlberger P, Nowotny G, Speiser P, **Joura E**, Sliutz G, Hefler L, Reinthaller A. Surgical treatment of endometrial cancer: does closure or non-closure of the vagina affect the local recurrence rate?
Anticancer Res. 2007;27:1589-91. , IF:1,479
177. Tringler B, Grimm C, Dudek G, Zeillinger R, Tempfer C, Speiser P, **Joura E**, Reinthaller A, Hefler LA. p16INK4a expression in invasive vulvar squamous cell carcinoma.
Appl Immunohistochem Mol Morphol. 2007;15:279-83 *, IF:1,474
178. Hefler LA, Grimm C, Six L, Seebacher V, Polterauer S, **Joura E**, Tempfer C, Sliutz G, Reinthaller A. Inguinal sentinel lymph node dissection vs. ccomplete inguinal lymph node dissection in patients with vulvar cancer.
Anticancer Res 2008;28:515-7 IF:1,414
179. Hefler L, Polterauer s, Nowotny G, Tempfer C, Kohlberger P, Sliutz G, Speiser P, **Joura E**, Reinthaller A. Necessitiy of colposcopy and biopsy prior to large loop excision of the transformation zone (LEETZ)
Anticancer Res 2008;28:519-21 IF:1,414
180. van Damme P, Pecorelli S, **Joura EA**. The introduction of policies for human papillomavirus vaccination in Europe.
J Public Health 2008;16:291-8 IF:1,238
181. **Joura EA**, Kjaer SK, Wheeler CM, Sigurdsson K, Iversen OE, Hernandez-Avila M, Perez G, Brown DR, Koutsky LA, Tay EH, García P, Ault KA, Garland SM, Leodolter S, Olsson SE, Tang GW, Ferris DG, Paavonen J, Lehtinen M, Steben M, Bosch X, Dillner J, Kurman RJ, Majewski S, Muñoz N, Myers ER, Villa LL, Taddeo FJ, Roberts C, Tadesse A, Bryan J, Lupinacci LC, Giacoletti KE, Lu S, Vuocolo S, Hesley TM, Haupt RM, Barr E. HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine.
Vaccine 2008;26:6844-51. *, IF:3,377
182. Six L, Leodolter S, Sings HL, Barr E, Haupt R, **Joura EA**. Prevalence of human papillomavirus types 6, 11, 16 and 18 in young Austrian women - baseline data of a phase III vaccine trial. Wien Klin Wochenschr 2008;120:666-671. *, IF:0,857
183. Brunner AH, Polterauer S, Tempfer C, **Joura E**, Reinthaller A, Horvat R, Hefler L. The accuracy of intraoperative frozen section of inguinal sentinel lymph node in vulvar cancer. Anticancer res 2008;28:4091-4 IF:1,414
184. Garland SM, Steben M, Sings HL, James M, Lu S, Railkar R, Barr E, Haupt RM, **Joura EA**. Natural history of genital warts: Analysis of the placebo arm of two randomized phase III trials of a quadrivalent HPV (types 6, 11, 16, 18) vaccine
J Infect Disease 2009;199:805-14 **, IF: 5,682
185. Doerfler D, Bernhaus A, Kottmel A, Sam C, Koelle D, **Joura EA**. HPV infection prior to coitarche.
Am J Obstet Gynecol 2009;200:487-91 ***, IF: 3,453

186. Brown DR, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Wheeler CM, Perez G, Koutsky LA, Tay HE; Garcia P, Ault KA, Garland SM, Leodolter S, **Joura EA**, Olsson SE, Tang GWK, Ferris DG, Paavonen J, Steben M, Bosch X, Dillner J, Kurman RJ, Majewski S, Munoz N, Myers ER, Villa LL, Taddeo FJ, Roberts C, Tadesse A, bryan J, Lupinacci, LC, Giacoletti KE, Sings HL, James M, Hesley TM, Barr E. The impact of quadrivalent HPV (type 6/11/16/18) L1 VLP vaccine on infection and disease due to oncogenic non-vaccine HPV types in generally HPV naïve women aged 16-26.
J Infect Dis 2009;199:926-35. ** , IF: 5,682
187. Wheeler CM, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Brown DR, Perez G, Koutsky LA, Tay HE; Garcia P, Ault KA, Garland SM, Leodolter S, **Joura EA**, Olsson SE, Tang GWK, Ferris DG, Paavonen J, Steben M, Bosch X, Dillner J, Kurman RJ, Majewski S, Munoz N, Myers ER, Villa LL, Taddeo FJ, Roberts C, Tadesse A, bryan J, Lupinacci, LC, Giacoletti KE, Sings HL, James M, Hesley TM, Barr E. The impact of quadrivalent HPV (type 6/11/16/18) L1 VLP vaccine on infection and disease due to oncogenic non-vaccine HPV types in sexually active women aged 16-26.
J Infect Dis 2009;199:936-44. ** , IF: 5,682
188. Garland SM, Insinga RP, Sings HL, Haupt RM, **Joura EA**. Human papillomavirus infection and vulvar disease.
Cancer Epidemiol Biomarkers Prev 2009;18:1777-84 ** , IF: 4,770
189. **Joura EA**, Garland SM. Cervical cancer after HPV vaccination. Letter to the editor. Obstet Gynecol 2009;114:17-5 ** , IF: 4,397
190. **Joura EA**: Vorurteile über die Sicherheit von HPV_ Impfungen. In Myths and misconceptions. Singer A, Jordan JA (eds) S W Health Ltd, London, UK 2009 Deutsche Auflage
191. **Joura E**. HPV- Impfung: Ein update zu Sicherheit und Wirksamkeit. Speculum
192. **Joura EA**. Cervical cancer and vaccination- an overview. Eur J Cancer 2009;45 S1:457-8 IF: 4,475
193. Kruger Kjaer S, Sigurdson K, Iversen OE, Hernandez -Avila M, Wheeler C, Perez G, Brown DR, Koutsky LA, Tay EH, Garcia P, Ault KA, Garland SM, Leodolter S, Olsson SE, Tang GW, Ferris DG, Paavonen J, Lehtinen M, Steben M, Bosch FX, Dillner J, **Joura EA**, Majewski S, Munoz N, Myers ER, Villa LL, Taddeo FJ, Roberts C, Tadesse A, Bryan J, Maansson R, Lu S, Vuocolo S, Hesley TM, Saah A, Barr E, Haupt RM. A pooled analyses of continued prophylactic efficacy of quadrivalent HPV vaccine against high grade cervical and external genital lesions. Cancer Prev Res 2009 ** , IF: 6,000
194. **Joura E**. Short term impact of Gardasil in HPV- naïve and HPV-exposed women, part 1: CIN, VIN, VaIN and genital warts. Cytopathology 2009;20/S1:74 S1 IF: 1,514

195. Jaura EA. Short term impact of Gardasil in HPV- naïve and HPV-exposed women, part 2: Pap tests, Colposcopy and definitive therapy. *Cytopathology* 2009;20/S1:173 S1 IF: 1,514

196. Olsson SE, Kruger Kjaer S, Sigurdson K, Iversen OE, Hernandez -Avila M, Wheeler C, Perez G, Brown DR, Koutsky LA, Tay EH, Garcia P, Ault KA, Garland SM, Leodolter S, Tang GW, Ferris DG, Paavonen J, Lehtinen M, Steben M, Bosch FX, Dillner J, Jaura EA, Majewski S, Munoz N, Myers ER, Villa LL, Taddeo FJ, Roberts C, Tadesse A, Bryan J, Maansson R, Vuocolo S, Hesley TM, Saah A, Barr E, Haupt RM.
Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type. *Hum Vaccin* 2009;5:696-04 [Epub ahead of print] *, IF: 1,940

197. Muñoz N, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Wheeler CM, Perez G, Brown DR, Koutsky LA, Tay EH, Garcia PJ, Ault KA, Garland SM, Leodolter S, Olsson SE, Tang GW, Ferris DG, Paavonen J, Steben M, Bosch FX, Dillner J, Huh WK, **Jaura EA**, Kurman RJ, Majewski S, Myers ER, Villa LL, Taddeo FJ, Roberts C, Tadesse A, Bryan JT, Lupinacci LC, Giacoletti KE, Singhs HL, James MK, Hesley TM, Barr E, Haupt RM.
Impact of Human Papillomavirus (HPV)-6/11/16/18 Vaccine on All HPV-Associated Genital Diseases in Young Women. *J Natl Cancer Inst* 2010;102:325-32 ***,
IF:14,697

198. Insinga RP, Perez G, Wheeler CM, Koutsky LA, Garland SM, Leodolter S, **Jaura EA**, Ferris DG, Steben M, Brown DR, Elbasha EH, Paavonen J, Haupt RM; FUTURE I Investigators.
Incidence, duration, and reappearance of type-specific cervical human papillomavirus infections in young women. *Cancer Epidemiol Biomarkers Prev* 2010;19:1585-94 **, IF:3,919

199. FUTURE I/II Study Group, Dillner J, Kjaer SK, Wheeler CM, Sigurdsson K, Iversen OE, Hernandez-Avila M, Perez G, Brown DR, Koutsky LA, Tay EH, Garcia P, Ault KA, Garland SM, **Leodolter S**, Olsson SE, Tang GW, Ferris DG, Paavonen J, Lehtinen M, Steben M, Bosch FX, **Jaura EA**, Majewski S, Muñoz N, Myers ER, Villa LL, Taddeo FJ, Roberts C, Tadesse A, Bryan JT, Maansson R, Lu S, Vuocolo S, Hesley TM, Barr E, Haupt R. Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial. *BMJ* 2010 Jul 20;341:c3493 *** , IF:13,471

200. Ault KA, **Jaura EA**, Kjaer SK, Iversen OE, Wheeler CM, Perez G, Brown DR, Koutsky LA, Garland SM, Olsson SE, Tang GW, Ferris DG, Paavonen J, Steben M, Bosch FX, Majewski S, Muñoz N, Singhs HL, Harkins K, Rutkowski MA, Haupt RM, Garner EI; for the FUTURE I and II Study Group.
Adenocarcinoma in situ and associated human papillomavirus type distribution observed in two clinical trials of a quadrivalent human papillomavirus vaccine. *Int J Cancer*. 2010 Oct 14. [Epub ahead of print] **, IF5,444

- 201.Monsonego J, Cortes J, Greppe C, Hampl M, **Joura E**, Singer A.
Benefits of vaccinating young adult women with a prophylactic quadrivalent
human papillomavirus (types 6, 11, 16 and 18) vaccine.
Vaccine 2010;28:8065-72. Epub 2010 Nov 16 *, IF:3,572
- 202.McCormack PL, **Joura EA**. Quadrivalent human papillomavirus (types 6, 11,
16, 18) recombinant vaccine (Gardasil®): a review of its use in the prevention
of premalignant genital lesions, genital cancer and genital warts in women.
Drugs 2010;70:2449-74 **, IF:4,226
- 203.Huh W, **Joura E**, Garland S, Paavonen J, Ferris D, Sings H, James M, Haupt
R.
Impact of quadrivalent HPV 6/11/16/18 vaccine in women who have undergone
definitive therapy.
Gynecol Oncol 2010;117:394 IF:3,733
- 204.Begovic H, Gatterer M, Pils S, Stani J, Wiener H, **Joura E**. A pilot study on L!
capsid protein in vulvar intraepithelial neoplasia.
Gebh Frauenheilk 2010;70:424 IF:0,354
- 205.Gatterer M, Pils S, Horvat R, Leodolter S, **Joura E**.
Proline, glutamic acid and leucine rich protein (PELP-1) is not a prognostic
marker for the epithelial ovarian cancer.
Gebh Frauenheilk 2010;70:425 IF:0,354
- 206.**Joura E**, Pils S, Gatterer M, Leodolter S. HPV- Impfung nur für junge
Mädchen?
WMW-Skriptum 2010;7(5): 18-9
- 207.**Joura EA**. Wer profitiert nicht von der HPV- Impfung?
Gyn-aktiv 5/2010
- 208.**Joura EA**. HPV- Impfung nur für junge Mädchen- wer soll geimpft werden?
Universum innere Medizin 9/2010:82-3
- 209.Brown DR, Garland SM, Ferris DG, **Joura E**, Steben M, James M, Radley D,
Vuocolo S, Garner EI, Haupt RM, Bryan JT. The humoral response to Gardasil
over four years as defined by Total IgG and competitive Luminex immunoassay.
Hum Vaccin 2011;7:230-8 *, IF: 3,577
- 210.Insinga RP, Perez G, Wheeler CM, Koutsky LA, Garland SM, Leodolter S,
Joura EA, Ferris DG, Steben M, Hernandez-Avila M, Brown DR, Elbasha E,
Munoz N, Paavonen J, Haupt RM; for the FUTURE I Investigators. Incident
Cervical HPV Infections in Young Women: Transition Probabilities for CIN and
Infection Clearance.
Cancer Epidemiol Biomarkers Prev 2011;20:287-296. **, IF: 4,123
- 211.Ault KA, **Joura EA**, Kjaer SK, Iversen OE, Wheeler CM, Perez G, Brown DR,
Koutsky LA, Garland SM, Olsson SE, Tang GW, Ferris DG, Paavonen J, Steben
M, Bosch FX, Majewski S, Muñoz N, Sings HL, Harkins K, Rutkowski MA, Haupt
RM, Garner EI; FUTURE I and II Study Group. Adenocarcinoma in situ and

associated human papillomavirus type distribution observed in two clinical trials of a quadrivalent human papillomavirus vaccine.

Int J Cancer 2011;128:1344-53.

******, IF: 5,444

212. Stoler MH, Vichnin MD, Ferenczy A, Ferris DG, Perez G, Paavonen J, **Joura EA**, Djursing H, Sigurdsson K, Jefferson L, Alvarez F, Sings HL, Lu S, James MK, Saah A, Haupt RM; FUTURE I, II and III Investigators. The accuracy of colposcopic biopsy: analyses from the placebo arm of the Gardasil clinical trials. Int J Cancer 2011;128:1354-62.

******, IF: 5,444

213. McCormack PL, **Joura EA**. Spotlight on quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine (Gardasil®) in the prevention of premalignant genital lesions, genital cancer, and genital warts in women. BioDrugs 2011;25:339-43.

*****, IF: 4,192

214. Haupt RM, Wheeler CM, Brown DR, Garland SM, Ferris DG, Paavonen JA, Lehtinen MO, Steben M, **Joura EA**, Giacoletti KE, Radley DR, James MK, Saah AJ, Sings HL; FUTURE I and II Investigators. Impact of an HPV6/11/16/18 L1 virus-like particle vaccine on progression to cervical intraepithelial neoplasia in seropositive women with HPV16/18 infection.

Int J Cancer 2011;129:2632-42.

******, IF: 5,444

215. **Joura EA**. Die HPV- Impfung: Stand des Wissens 2011. krebs:hilfe! 2011;1:3-4.

216. **Joura EA**. Studien zur HPV- Vakzine an der Universitätsklinik für Frauenheilkunde Wien. Speculum 2011;29(3):19-21

217. **Joura EA**, Garland SM, Paavonen J, Ferris DG, Perez G, Ault KA, Huh WK, Sings SL, James MK, Haupt RM, FUTURE I&II Study group. Effect of the human papillomavirus (HPV) quadrivalent vaccine in a subgroup of women with cervical and vulvar disease: retrospective pooled analysis of trial data.

BMJ 2012;344:e1401

*******, IF: 14,095

218. Tjalma WA, Fiander A, Reich O, Powell N, Nowakowski AM, Kirschner B, Koiss R, O'Leary J, **Joura EA**, Rosenlund M, Colau B, Schledermann D, Kukk K, Damaskou V, Repanti M, Vladareanu R, Kolomiets L, Savicheva A, Shipitsyna E, Ordi J, Molijn A, Quint W, Raillard A, Rosillon D, De Souza SC, Jenkins D, Holl K; for the HERACLES/SCALE Study Group. Differences in human papillomavirus type distribution in high-grade cervical intraepithelial neoplasia and invasive cervical cancer in Europe.

Int J Cancer 2013;132:854-67

******, IF: 5,444

219. Clark LR, Myers ER, Huh W, **Joura EA**, Paavonen J, Perez G, James MK, Sings HL, Haupt RM, Saah AJ, Garner EIO. Clinical trial experience with prophylactic HPV 6/11/16/18 vaccine in young black women.

J Adolescent Health 2013;52:322-9

*******, IF: 3,334

220. **Joura EA**. HPV Impfung wirkt auch nach der Erkrankung
Gyn aktiv 2012;5:48-9

- 221.**Joura EA**. HPV: Erkrankungen und primäre Prävention.
diePUNKTE: Gynäkologie Diplomfortbildung 2012;1:3-7
- 222.**Joura EA**. HPV Impfung: Stand des Wissens 2012
Spectrum Urologie 2012;1:66-7
- 223.**Joura EA**. HPV- Impfung: State of the art 2012
Jatros 2012;3:36-7
- 224.de Sanjosé S, Alemany L, Ordi J, Tous S, Alejo M, Bigby SM, **Joura EA**,
Maldonado P, Laco J, Bravo IG, Vidal A, Guimerà N, Cross P, Wain GV, Petry
KU, Mariani L, Bergeron C, Mandys V, Sica AR, Félix A, Usubutun A, Seoud M,
Hernández-Suárez G, Nowakowski AM, Wilson G, Dalstein V, Hampl M,
Kasamatsu ES, Lombardi LE, Tinoco L, Alvarado-Cabrero I, Perrotta M, Bhatla
N, Agorastos T, Lynch CF, Goodman MT, Shin HR, Viarheichyk H, Jach R, Cruz
MO, Velasco J, Molina C, Bornstein J, Ferrera A, Domingo EJ, Chou CY, Banjo
AF, Castellsagué X, Pawlita M, Lloveras B, Quint WG, Muñoz N, Bosch FX;
HPV VVAP study group.
Worldwide human papillomavirus genotype attribution in over 2000 cases of
intraepithelial and invasive lesions of the vulva.
Eur J Cancer.2013;49:3450-61 ** , IF: 5.061
- 225.Rössler L, Reich O, Horvat R, Collas de Souza S, Holl K, **Joura EA**
Human Papillomavirus in high-grade cervical lesions: Austrian data of a
European multicenter study.
Wien Klin Wochenschr 2013;125:591-9 *, IF: 0.831
- 226.**Joura EA**, Salat A. Humande Papillomaviren: Erkrankungen und Impfung.
krebs!hilfe 6/2013:9-11
- 227.Bresse X, Goergen C, Prager B, **Joura E**. Universal vaccination with the
quadrivalent HPV vaccine in Austria: impact on virus circulation, public health
and cost-effectiveness analysis.
Expert Rev Pharmacoecon Outcomes Res 2014;14:269-81. *,IF: 1,67
- 228.Pils S, **Joura EA**, Winter MP, Shrestha A, Jaeger-Lansky A, Ott J. What do
women with gynecologic cancer know about HPV and their individual disease?
A pilot study.
BMC Cancer 2014;14:388. doi: 10.1186/1471-2407-14-388 *,IF:3,32
- 229.**Joura EA**, Wiedermann U. HPV-Impfung im Nationalen Impfprogramm:
Frauenärzte weiterhin wichtige „Opinion-Leader“.
Speculum 2014;32(2):20-3
- 230.**Joura EA**, Ault KA, Bosch FX, Brown D, Cuzick J, Ferris D, Garland SM,
Giuliano AR, Hernandez-Avila M, Huh W, Iversen OE, Kjaer SK, Luna J, Miller
D, Monsonogo J, Munoz N, Myers E, Paavonen J, Pitisuttithum P, Steben M,
Wheeler CM, Perez G, Saah A, Luxembourg A, Sings HL, Velicer C. Attribution
of 12 high-risk human papillomavirus genotypes to infection and cervical
disease. Cancer Epidemiol Biomarkers Prev. 2014;23:1997-2008

231. Alemany L, Saunier M, Tinoco L, Quirós B, Alvarado-Cabrero I, Alejo M, **Joura EA**, Maldonado P, Klaustermeier J, Salmerón J, Bergeron C, Petry KU, Guimerà N, Clavero O, Murillo R, Clavel C, Wain V, Geraets DT, Jach R, Cross P, Carrilho C, Molina C, Shin HR, Mandys V, Nowakowski AM, Vidal A, Lombardi L, Kitchener H, Sica AR, Magaña-León C, Pawlita M, Quint W, Bravo IG, Muñoz N, de Sanjosé S, Bosch FX; HPV VVAP study group. Large contribution of human papillomavirus in vaginal neoplastic lesions: a worldwide study in 597 samples. *Eur J Cancer*. 2014;50:2846-54 **, IF: 5,417
232. **Joura EA**, Giuliano AR, Iversen OE, Bouchard C, Mao C, Mehlsen J, Moreira ED Jr, Ngan Y, Petersen LK, Lazcano-Ponce E, Pitisuttithum P, Restrepo JA, Stuart G, Woelber L, Yang YC, Cuzick J, Garland SM, Huh W, Kjaer SK, Bautista OM, Chan IS, Chen J, Gesser R, Moeller E, Ritter M, Vuocolo S, Luxembourg A; Broad Spectrum HPV Vaccine Study. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. *N Engl J Med* 2015;372:711-23 ***, IF:55,87
233. Kosalaraksa P, Mehlsen J, Vesikari T, Forstén A, Helm K, Van Damme P, **Joura EA**, Ciprero K, Maansson R, Luxembourg A, Sobanjo-Ter Meulen A. An Open-Label, Randomized Study of a Nine-valent Human Papillomavirus Vaccine Given Concomitantly with Diphtheria, Tetanus, Pertussis, and Poliomyelitis Vaccine in Healthy Adolescents 11 to 15 Years of Age *Pediatr Infect Dis J* 2015;34:627-34 **, IF: 3,135
234. Luxembourg A, Brown D, Bouchard C, Giuliano AR, Iversen OE, **Joura EA**, Penny ME, Restrepo JA, Romaguera J, Maansson R, Moeller E, Ritter M, Chen J. Phase II studies to select the formulation of a multivalent HPV L1 virus-like particle (VLP) vaccine. *Hum Vaccin Immunother*. 2015;11:1313-22. *, IF: 2,146
235. **Joura EA**, Bautista O, Luxembourg A. A 9-Valent HPV Vaccine in Women. *N Engl J Med*. 2015;372:2568-9. ***, IF: 55,87
236. Pils S, **Joura EA**. From the monovalent to the ninevalent HPV vaccine *Clin Microbiol Infect* 2015; 21:827-33. ***, IF: 5,77
237. Boiron L, **Joura E**, Langeron N, Prager B, Nikoglou T. Estimating The Cost-Effectiveness Profile of A Universal Vaccination Programme With A Nine-Valent Hpv Vaccine In Austria. *Value Health*. 2015;18(7):A585. doi:10.1016/j.jval.2015.09.1963. Epub 2015 Oct 20. **, IF: 3,828
- 238.3: Holl K, Nowakowski AM, Powell N, McCluggage WG, Pirog EC, Collas De Souza S, Tjalma WA, Rosenlund M, Fiander A, Castro Sánchez M, Damaskou V, **Joura EA**, Kirschner B, Koiss R, O'Leary J, Quint W, Reich O, Torné A, Wells M, Rob L, Kolomiets L, Molijn A, Savicheva A, Shipitsyna E, Rosillon D, Jenkins D. Human papillomavirus prevalence and type-distribution in cervical glandular neoplasias: Results from a European multinational epidemiological study. *Int J Cancer*. 2015;137:2858-68. **, IF:5,531

- 239.**Joura EA**, Pils S. How can we achieve HPV control in Europe?
Future Virol 2015;10:1125-7. ,IF:1,01
- 240.**Joura EA**. Der HPV Test in der Prävention des Zervixkarzinoms.
dfp Fortbildungsartikel
die Punkte/Gynäkologie 02/2016
- 241.**Joura EA**. HPV: Erkrankungen und primäre Prävention.
dfp Fortbildungsartikel
die Punkte/Gynäkologie 02/2016
- 242.Van Damme P, Bonanni P, Bosch FX, **Joura E**, Kjaer SK, Meijer CJ, Petry KU, Soubeyrand B, Verstraeten T, Stanley M. Use of the nonavalent HPV vaccine in individuals previously fully or partially vaccinated with bivalent or quadrivalent HPV vaccines.
Vaccine 2016;34:757-61. *,IF:3,624
- 243.**Joura E**, Clark L, Luxembourg A. Additional protection from 9-Valent HPV vaccine if administered before HPV exposure.
Am Fam Physician 2016;93:254-6. ,IF:0,13
- 244.Boiron L, **Joura E**, Largeron N, Prager B, Uhart M. Estimating the cost-effectiveness profile of a universal vaccination programme with a nine-valent HPV vaccine in Austria.
BMC Infect Dis 2016;16:153. doi:10.1186/s12879-016-1483-5. *,IF: 2,17
- 245.Moreira ED Jr, Block SL, Ferris D, Giuliano AR, Iversen OE, **Joura EA**, Kosalaraksa P, Schilling A, Van Damme P, Bornstein J, Bosch FX, **Pils S**, Cuzick J, Garland SM, Huh W, Kjaer SK, Qi H, Hyatt D, Martin J, Moeller E, Ritter M, Baudin M, Luxembourg A. Safety profile of the 9-Valent HPV vaccine: A combined analysis of 7 Phase III clinical trials.
Pediatrics 2016;138. pii:e20154387. ***,IF:5,705
- 246.Pils S, Promberger R, Springer S, **Joura E**, Ott J. Decreased ovarian reserve predicts inexplicability of recurrent miscarriage? A retrospective analysis.
PloS One. 2016;11: e0161606. **,IF:3,54
- 247.Castellsague X, Ault KA, Bosch FX, Brown D, Cuzick J, Ferris DG, **Joura EA**, Garland SM, Giuliano AR, Hernandez-Avila M, Huh W, Iversen OE, Kjaer SK, Luna J, Monsonogo J, Munoz N, Myers E, Paavonen J, Pitisuttihum P, Steben M, Wheeler CM, Perez G, Saah A, Luxembourg A, Sings HL, Velicer C. Human papillomavirus detection in cervical neoplasia attributed to 12 high-risk human papillomaviruses genotypes by region.
Papillomavirus Research 2016;2:61-69 ,CS 4.07
- 248.Gensthaller L, Pils S, Alemany L, Horvat R, Stani J, Polterauer S, de Sanjose S, Joura EA. Die HPV Prävalenz in Vulvakarzinomen in Österreich. Geburtshilfe Frauenheilkd 2016;76:A7 doi:10.1055/s-0036-1579590
- 249.Braune G, Fiedler T, Hefler L, Joura E, Kölbl H, Marth C, Reinthaller A, Zeimet A. HPV task Force der OEGGG: Positionspapier zum HPV Screening

Frauenarzt 5/2016

250.Joura EA, Pils S. Der nonavalente HPV Impfstoff
Gynaktiv 2/2016

251.Pils S, Joura EA. HPV Impfung aktuell
Spectrum Onkologie 2/2016

252.Joura EA. Die Zukunft des Zervixkarzinomscreening in Österreich
Speculum 2016

253.**Joura EA**, Pils S. Vaccines against HPV infections: protection against cancer warts or both.
Clin Microbiol Infect 2016;22:S125-7 ***;IF: 5,768

254.Petersen LK, Restrepo J, Moreira ED, Iversen OE, Pitisuttithum P, Van Damme P, **Joura EA**, Olsson SE, Ferris D, Block S, Giuliano AR, Bosch X, Pils S, Cuzick J, Garland SM, Huh W, Kjaer SK, Bautista O, Hyatt D, Maansson R, Moeller E, Qi H, Roberts C, Luxembourg A. Impact of baseline covariates on the immunogenicity of the 9-valent HPV vaccine – a combined analyses of five phase III clinical trials.
Papillomavirus Res 2017;3:105-15 ,CS: 4.07

255.Raphaelis S, Mayer H, Ott S, Mueller MD, Steiner E, **Joura E**, Senn B. The Impact of Written Information and Counseling (WOMAN-PRO II Program) on Symptom Outcomes in Women with Vulvar Neoplasia: A Multicenter Randomized Controlled Phase II Study
Gynecol Oncol 2017;146:114-22 ***; IF: 4.198

256.Guevara A, Cabello R, Woelber L, Moreira ED, **Joura E**, Reich O, Shields C, Ellison M, Joshi A, Luxembourg A. Antibody persistence and evidence of immune memory at 5 years following administration of the 9-valent HPV vaccine
Vaccine 2017;35:5050-7 *, IF: 3.325

257.Huh W, **Joura EA**, Giuliano AR, IversenOE, Rosires Pereira de Andrade, Ault KA, Bartholomew D, Cestero RM, Fedrizzi EN, Hirschberg AL, Mayrand MH, Ruiz-Sternberg AM, Stapleton JT, Wiley DJ, Ferenczy A, Kurman R, Ronnett BM, Stoler MH, Cuzick J, Garland SM, Kjaer SK, Bautista OM, Haupt R, Moeller E, Ritter M, Roberts CC, Shields C, Alain Luxembourg A. Efficacy, Immunogenicity, and safety of a nine-valent human papillomavirus vaccine in women aged 16-26 years: Final analyses of a randomised, double-blind trial.
Lancet 2017;390:2143-59 ***;IF: 47.831

258.**Pils S, Gensthaler L**, Alemany L, Horvat R, de Sanjose S, **Joura EA**. HPV prevalence in vulvar cancer in Austria
Wien Klin Wochenschr 2017;129:805-9 *, IF:0.974

259.Moreira E, Giuliano AR, de Hoon J, Iversen OE, **Joura EA**, Restrepo J, Van Damme P, Vandermeulen C, Ellison MC, Krick A, Shields C, Heiles B, Luxembourg A. Safety profile of the 9-valent human papillomavirus vaccine: assessment in prior quadrivalent HPV vaccine recipients and in men 16 to 26

- years of age
Hum Vacc Immunother 2018;14:396-403 *, IF: 2,157
260. Petry KU, Bollaerts K, Bonanni P, Stanley M, Drury R, **Joura E**, Kjaer SK, Meijer CJLM, Riethmuller D, Soubeyrand B, Van Damme P, Bosch X. Estimation of the individual residual risk of cervical cancer after vaccination with the nonavalent HPV vaccine.
Hum Vacc Immunother 2018;14:1800-6 *, IF: 2,157
261. Schuster S, **Joura E**, **Kohlberger P**. Natural History of Squamous Intraepithelial Lesions in Pregnancy and Mode of Delivery.
Anticancer Res 2018;38:2439-2442 *, IF: 1,865
262. Bekos C, Schwameis R, Heinze G, Gärner M, Grimm C, **Joura E**, Horvat R, Polteraue S, Polteraue M. Influence of age on histologic outcome of cervical intraepithelial neoplasia during observational management: results from large cohort, systematic review, meta-analysis.
Sci Rep 2018;8:6383 **, IF: 4,122
263. Garland SM, **Joura EA**, Ault KA, F. Bosch X, Brown DR, Castellsague X, Alex Ferenczy A, Ferris DG⁷, Giuliano AR, Hernandez-Avila M, Huh WK, Iversen OE, Kjaer SK, Kurman RJ, Luna J, Monson J, Muñoz N, Paavonen J, Pitisuttithum P, Brigitte M. Ronnett BM, Steben M, Stoler MH, Wheeler CM, Wiley DJ, Perez G, Alfred J. Saah AJ, Luxembourg A, Li S, DiNubile MJ, Wagner M, Velicer C. Vaginal and vulvar intraepithelial neoplasia in young women attributed to 14 Human Papillomavirus genotypes.
Obstet Gynecol 2018 ;132 :261-70 ***, IF : 5,426
264. Ghelardi A, Parazzini F, Martella F, Pieralli A, Bay P, Tonetti A, Svelato A, Lombardi S, Bertacca G, **Joura EA**.
SPERANZA project: HPV vaccination after treatment for CIN2+.
Gynecol Oncol 2018;151:229-34 ***, IF: 4,540
265. Reich O, Braune G, Eppel W, Fiedler T, Graf A, Hefler L, **Joura E**, Kölbl H, Marth C, Pokieser W, Regitnig P, Reinthaller A, Tamussino K, Widschwendter A, Zeimet A, Kohlberger P. Joint Guideline of the OEGGG, AGO, AGK and ÖGZ on the Diagnosis and Treatment of Cervical Intraepithelial Neoplasia and Appropriate Procedures When Cytological Specimens Are Unsatisfactory.
Gebhilfe Frauenheilkd 2018;78:1232-44 *, IF: 1,291
266. Giuliano AR, **Joura EA**, Garland SM, Huh W, Iversen OE, Kjaer SK, Ferenczy A, Stoler MH, Bautista OM, Moeller E, Ritter M, Shields C, Luxembourg A. 9-valent HPV vaccine efficacy against related diseases and definitive therapy: Comparison with historic placebo population.
Gynecol Oncol 2019;154:110-7. ***, IF: 4,540
267. **Joura EA**, Kyrgiou M, Bosch FX, Kesic V, Nieminen P, Redman C, Gültekin M. The ESGO-EFC position paper of the European Society of Gynecologic Oncology and the European Federation of Colposcopy

268. Bekos C, Polterauer S, Seebacher V, Bartl T, **Joura E**, Reinthaller A, Sturdza A, Horvat R, Schwameis R, Grimm C. Pre-operative hypoalbuminemia is associated with complication rate and overall survival in patients with vulvar cancer undergoing surgery. Arch Gynecol Obstet 2019;300:1015-22.
*,IF 2,199
269. **Joura E**, Jenkins D, Guimera N. Vulvar, Penile and Scrotal Human Papillomavirus and non-Human Papillomavirus Cancer Pathways. In: Jenkins D, Bosch FX (eds.) Human Papillomavirus- proving and using viral cause for cancer. Academic Press (Elsevier), London 2019
270. V Paspalj, R Schwameis, S Pils, R Ristl, E Joura
HPV vaccination and recurrent disease after conization: a meta-analysis (P41)
Int J Gynecol Cancer 2019, 29 (Suppl 4) A75-A76; DOI: 10.1136/ijgc-2019-ESGO.103
271. Gensthaler L, **Joura EA**, Alemany L, Horvat R, de Sanjose S, Pils S. The impact of p16^{ink4a} positivity in invasive vulvar cancer on disease-free and disease-specific survival, a retrospective study.
Arch Gynecol Obstet 2020;301:753-9
*,IF 2,199
272. Joura EA, Pils S. Update zur HPV Impfung
GYN AKTIV 1/2020
273. Ferris DG, Brown D, Giuliano AR, Myers E, **Joura EA**, Garland SM, Kjaer SK, Perez G, Saah A, Luxembourg A. Prevalence, incidence, and natural history of HPV infection in adult women ages 24 to 45 participating in a vaccine trial.
Papillomavirus Res 2020;10:100202
274. Ciavattini A, Delli Carpini G, Giannella L, Arbyn M, Kyrgiou M, **Joura EA**, Sehouli J, Carcopino X, Redman CW, Nieminen P, Cruickshank M, Gultekin M. European Federation for Colposcopy (EFC) and European Society of Gynaecological Oncology (ESGO) joint considerations about human papillomavirus (HPV) vaccination, screening programs, colposcopy, and surgery during and after the COVID-19 pandemic.
Int J Gynecol Cancer 2020;30:1097-1100.
*,IF 2.095
275. Bonanni P, Faivre P, Lopalco PL, **Joura EA**, Bergroth T, Varga S, Gemayel N, Drury R. The status of human papillomavirus vaccination recommendation, funding, and coverage in WHO Europe countries (2018-2019).
Expert Rev Vaccines. 2020 Dec 14:1-11.
*,IF 1.746
276. Trutnowsky G, Reich O, Joura EA, Ciresa A, Widschwendter A, Schauer C, Bogner G, Ziga J, Boandl A, Tamussino K. Primary imiquimod treatment versus surgery for vulvar intraepithelial neoplasia – PITVIN study. Baseline Results of a Randomized Clinical Trial. Int J Gynecol Cancer 2020;30S4:A108

277. Ghelardi A, Marrai R, Bogani G, Sopracordevole F, Bay P, Tonetti A, Lombardi S, Bertacca G, **Joura EA**. Surgical Treatment of vulvar HSIL: Adjuvant HPV vaccine reduces recurrent disease. *Vaccines* 2020;9:83 *, IF 4,086
278. Stanley M, **Joura E**, Yen GP, Kothari S, Luxembourg A, Saah A, Walia A, Perez G, Khoury H, Badgley D, Brown DR. Systematic literature review of neutralizing antibody immune responses to non-vaccine targeted high-risk HPV types induced by the bivalent and the quadrivalent vaccines. *Vaccine* 2021;39:2214-2223 *, IF 3.143
279. Brown DR, **Joura EA**, Kothari S, Luxembourg A, Saah AJ, Walia AJ, Perez G, Hanane Khoury H, Badgley D, Stanley M, Yen G. Systematic literature review of neutralizing antibody immune responses to non-vaccine targeted high-risk HPV types induced by the bivalent and the quadrivalent vaccines *Vaccine* 2021;39:2224-2236 *, IF 3.143
280. **Joura EA**, Ulied A, Vandermeulen C, Rua Figueroa M, Seppä I, Hernandez Aguado JJ, Ahonen A, Reich O, Virta M, Perino A, Peris Tuser M, Peters K, Orioni M, Raspagliesi F, Tjalma WAA, Tummers P, Woelber L, Nieminen P, van Damme P, Sehoul J, Fiol Ruiz G, Brucker S, Fehm T, Cheon K, Rawat S, Luxembourg A, Wittke F. Immunogenicity and safety of a nine-valent HPV vaccine in women 27-45 years of age compared to women 16-26 years of age: An open-label phase III study. *Vaccine* 2021;39:2800-9. *, IF 3.143
281. **Joura EA**, Joura MJ. Warum ist die HPV Impfung für Jungen sinnvoll *Gynäkologe* 2021;54:796-800
282. Trutnovsky G, Reich O, **Joura EA**, Ciresa A, Widschwendter A, Schauer C, Bogner G, Ziga J, Boandl A, Tamussino K. Primary imiquimod treatment versus surgery for vulvar intraepithelial neoplasia – PITVIN study. A Randomized Clinical Trial. *Int J Gynecol Cancer* 2021;A376-7. **, IF 4.678
283. **Joura EA**. Ergibt die HPV Impfung nach Kondylomen Sinn? *Krebs:hilfe!* 1/2022
284. Polterauer S, Reich O, Widschwendter A, Hadjari L, Bogner G, Reinthaller A, **Joura E**, Trutnovsky G, Ciresa-Koenig A, Ganhoer-Schimboeck J, Boehm I, Berger R, Langthaler E, Aberle SW, Heinze G, Gleiss A, Grimm C. Topical imiquimod compared with conization to treat cervical high-grade squamous intraepithelial lesions: Multicenter, randomized controlled trial. *Gynecol Oncol* 2022;165:23-29. **, IF 5.304
285. Trutnovsky G, Reich O, **Joura EA**, Holter M, Ciresa-König A, Widschwendter A, Schauer C, Bogner G, Jan Z, Boandl A, Kalteis MS, Regauer S, Tamussino K. Topical imiquimod versus surgery for vulvar intraepithelial neoplasia: a multicentre, randomised, phase 3, non-inferiority trial. *Lancet* 2022 Apr 25:S0140-6736(22)00469-X ***, IF 202.731

- 286.Preti M, **Joura EA**, Viera-Baptista P, et al. The European Society of Gynaecological Oncology (ESGO), the International Society for the Study of Vulvovaginal Disease (ISSVD), the European College for the Study of Vulval Disease (ECSVD) and the European Federation for Colposcopy (EFC) Consensus Statements on Pre-Invasive Vulvar Lesions VIN
Int J Gynecol Cancer 2022;32:830-45 ** , IF 4.678
- 287.Preti M, **Joura EA**, Viera-Baptista P, et al. The European Society of Gynaecological Oncology (ESGO), the International Society for the Study of Vulvovaginal Disease (ISSVD), the European College for the Study of Vulval Disease (ECSVD) and the European Federation for Colposcopy (EFC) Consensus Statements on Pre-Invasive Vulvar Lesions VIN
J Low Genit Tract Di 2022;26:229-44 ** , IF 3.842
- 288.Taumberger N, **Joura EA**, Arbyn M, Kyrgiou M, Sehouli J, Gultekin M
Myths and Fake Messages about HPV Vaccination: Answers from the ESGO Prevention Committee
Int J Gynecol Cancer 2022;32:1316-20. ** , IF 4.678
- 289.Maldonado I, Plata M, Gonzales M, Correa A, Nossa C, Giuliano AR, **Joura EA**, Ferenczy A, Ronnet BM, Stoler MH, Zhou HJ, Joshi A, Das R, Bautista O, Group T, Luxembourg A, Saah A, Buchwald UK. Effectiveness, Immunogenicity, and Safety of the Quadrivalent HPV Vaccine in Women and Men Aged 27–45 Years.
Human Vaccines and Immunotherapeutics 2022;18:5, 2078626 *,IF 3,452
- 290.Giuliano AM, **Joura EA**. The time to act is now:elimination of cervical and other cancers caused by HPV in women and men.
www.HPVWorld.com, 211
- 291.Pils S, Mlakar J, Poljak M, Domjanič GG, Kaufmann U, Springer S, Salat A, Langthaler E, **Joura EA**. HPV screening in the urine of transpeople - A prevalence study. EClinicalMedicine. 2022;54:101702. *** , IF17.033
- 292.Pils S, Joura EA: HPV, in: Context, Principles and Practice of Transgynecology, Eds: Mick van Trotsenburg, Rixt Luikenaar, Cristina Maria Meriggiola
Cambridge University Press 2023
- 293.**Joura EA**: HPV.
In: FAQ in Kinder- und Jugendgynäkologie. Oppelt P, Lehman-Kannt S (eds)
Springer 2022
- 294.Kesic V, Carcopino X, Preti M, Vieira-Baptista P, Bevilacqua F, Bornstein J, Chargari C, Cruickshank M, Erzeneoglu E, Gallio N, Gultekin M, Heller D, **Joura E**, Kyrgiou M, Madić T, Planchamp F, Regauer S, Reich O, Esat Temiz B, Woelber L, Zodzika J, Stockdale C. The European Society of Gynaecological Oncology (ESGO), the International Society for the Study of Vulvovaginal Disease (ISSVD), the European College for the Study of Vulval Disease (ECSVD), and the European Federation for Colposcopy (EFC) Consensus Statement on the Management of Vaginal Intraepithelial Neoplasia.

J Low Genit Tract Dis. 2023;27(2):131-145. IF:2.4

295.Kesic V, Carcopino X, Preti M, Vieira-Baptista P, Bevilacqua F, Bornstein J, Chargari C, Cruickshank M, Erzenoglu E, Gallio N, Gultekin M, Heller D, **Joura E**, Kyrgiou M, Madić T, Planchamp F, Regauer S, Reich O, Esat Temiz B, Woelber L, Zodzika J, Stockdale C. The European Society of Gynaecological Oncology (ESGO), the International Society for the Study of Vulvovaginal Disease (ISSVD), the European College for the Study of Vulval Disease (ECSVD), and the European Federation for Colposcopy (EFC) consensus statement on the management of vaginal intraepithelial neoplasia. Int J Gynecol Cancer. 2023;33(4):446-461. IF:4.1

296.Kamani MO, Kyrgiou M, **Joura E**, Zapardiel I, Grigore M, Arbyn M, Preti M, Planchamp F, Gultekin M. ESGO Prevention Committee opinion: is a single dose of HPV vaccine good enough? Int J Gynecol Cancer. 2023;33(4):462-464. IF:4.1

297.Paternostro C, **Joura EA**, Ranftl C, Langthaler EM, Ristl R, Dorittke T, Pils S. Rate of Involved Endocervical Margins According to High-Risk Human Papillomavirus Subtype and Transformation Zone Type in Specimens with Cone Length ≤ 10 mm versus > 10 mm-A Retrospective Analysis. Life (Basel). 2023;13(8):1775. IF:3.2

298.Reuschenbach M, Doorbar J, Del Pino M, **Joura EA**, Walker C, Drury R, Rauscher A, Saah AJ. Prophylactic HPV vaccines in patients with HPV-associated diseases and cancer. Vaccine. 2023;41(42):6194-6205. IF:4.5

299.**Joura EA**. HPV vaccination. In: ESGO Textbook of Gynaecological Oncology (Platinum Edition) Ayhan A, Fagotti A, Gultekin M, Pakiz M, Querleu D, Reed N, Taskiran C (eds). Gunes Publishing Istanbul 2023

300.Angeles MA, De Vitis LA, Cucinella G, Bonaldo G, Bizzarri N, Agusti N, Kacperczyk-Bartnik J, El Hajj H, Theofanakis C, Bilir E, Hsu HC, Estrada EE, Pareja R, Fotopoulou C, du Bois A, Plante M, Rauh-Hain JA, Mirza MR, Monk BJ, Gultekin M, **Joura E**, Fagotti A, Ramirez PT. Highlights from the 24th European Congress on Gynaecological Oncology in Istanbul: an ENYGO-IJGC Fellows compilation. Int J Gynecol Cancer. 2024;34(2):190-196 IF:4.1

301.Del Pino M, Vorsters A, Joura EA, Doorbar J, Haniszewski M, Gudina IA, Kodjamanova P, Velicer C, Drury R. Risk factors for human papillomavirus infection and disease: A targeted literature summary. J Med Virol. 2024 Feb;96(2):e29420. IF:6.8

302.Paternostro C, Joura EA, Ott J, Ghobrial S, Langthaler EM, Pils S. ECC at LLETZ-An Exploratory Retrospective Cohort Study. J Clin Med 2024;13(22):6671. doi: 10.3390/jcm13226671. IF:3.0

303.Bizzarri N, Kyrgiou M, De Vincenzo R, Zapardiel I, Razumova Z, Taumberger N, Toth I, Theofanakis C, Gultekin M, **Joura EA**. Prophylactic HPV vaccination in HPV-related gynecologic cancers: European Society of Gynecological

304. Vaessen VJGM, van de Laar RLO, Piso-Jozwiak M, Dalm VASH, **Joura EA**, Jentschke M, van Beekhuizen HJ. Adjuvant nonavalent HPV vaccination in women treated for vulvar HSIL, a randomized placebo-controlled trial; VulVaccin study protocol. BMC Cancer. 2025 May 20;25(1):903.
305. Kacperczyk-Bartnik J, El Hajj H, Tóth I, Bizzarri N, Tóth R, Razumova Z, Zwimpfer TA, Taumberger N, Bilir E, Strojna A, Angeles MA, Gasimli K, Nikolova T, Bartnik P, Cokan A, Sari SY, Kahramanoglu I, Caruso G, **Joura EA**, Kyrgiou M, Kesic V, Fagotti A, Arbyn M, Gultekin M. Declaration on cervical cancer elimination: literature review and perspectives from early-career clinicians. Int J Gynecol Cancer. 2025 Jul;35(7):101902.
306. Preti M, Gallio N, Bornstein J, **Joura E**, Saçintı KG, Baptista PV. The future of research on vulvar intraepithelial neoplasia: towards precision diagnostics and risk stratification. J Turk Ger Gynecol Assoc. 2025;26(3):230-234.
307. Bornstein J, Vieira-Baptista P, Stockdale C, Preti M, **Joura E**, Schejter E. The challenging approach to the management of male partners of HPV-positive women. Hum Vaccin Immunother. 2025;21(1):2515753.
308. Chromy D, Aigner F, Becker JC, Bickel M, Brunner A, Classen J, Hampl M, Helbig D, Hentrich M, Hetzer F, Hoffmann C, Jongen J, **Joura E**, Kirnbauer R, Kreuter A, Lang GF, Mokhles M, Oellig F, Oette M, Potthoff A, Rink AD, Salat A, Schmidt AJ, Siegel R, Stary G, Werner RN, Weyandt G, Wieland U, Esser S. German-Austrian guideline on screening for anal dysplasia and anal carcinoma in people living with HIV. J Dtsch Dermatol Ges. 2025 Aug;23(8):1025-1040.
309. Taumberger N, Friko I, Der VM, Ellis LB, Shearer AM, Bowden SJ, Kyrgiou M, Pan TL, Lessiak V, Hofer N, Rogatsch E, Nanda M, Pfniss I, **Joura E**, Cinar A, Kilic Y, Gultekin M. Implementing High-Risk Human Papillomavirus Self-Sampling for Cervical Cancer Screening in Ghana: A Study (CarciSCAN) Protocol. Cancer Control. 2025;32:10732748251330698.
310. **Joura E**, Kjaer SK, Bautista O, Luxembourg A, Saah A, Giuliano A. Effect of prior 9-Valent HPV vaccination on subsequent lower genital tract dysplasia after cervical excisional surgery. Obstet Gynecol 2025 in press